- 作者：Yoshio Yoshida ; Tetsuji Kurokawa ; Yoko Sawamura ; Akiko Shinagawa ; Hidehiko Okazawa ; Yasuhisa Fujibayashi ; Fumikazu Kotsuji
- 关键词：FES-PET ; Endometrial cancer ; Endocrine treatment
- 刊名：Gynecologic Oncology
- 出版年：2007
- 期刊代码：295_00908258
- 类别：med
- 出版时间：March 2007
- 卷：104
- 期：3
- 页码：764-766
- 文件大小：544 K
The positron emission tomography (PET) with F18 17β-estradiol (FES) has good imaging for assessment of estrogen receptor in breast cancer.
Case.
We report on a 30-year-old woman who desired to preserve her fertility with well-differentiated endometrial adenocarcinoma. Before hormone treatment was started, FES-PET showed increased uptake of endometrium, magnetic resonance imaging (MRI) showed thickness and F-18 fluorodeoxyglucose (FDG)-PET showed increased uptake. FES-PET after 3 months showed remaining FES uptake, but there were no abnormal findings on MRI and FDG-PET. Hysteroscopy showed remaining adenocarcinoma. After additional treatment, FES-PET showed a therapeutic response, and hysteroscopy showed no abnormal finding.
Conclusions.
To our knowledge, this is the first report that FES-PET has the potential to provide more useful information than did FDG-PET about the hormone therapy.